Ngā hua rapu - G. Charpentier

Whakamahine hua
  1. 1
    Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

    Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus mā André Scheen, G. Charpentier, Carl Johan Östgren, Åsa Hellqvist, Ingrid Gause‐Nilsson

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

    Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-M... mā Coralie Amadou, Sylvia Franc, Pierre‐Yves Benhamou, Sandrine Lablanche, Erik Huneker, G. Charpentier, A. Penfornis

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    One‐year real‐world performance of the <scp>DBLG1</scp> closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany

    One‐year real‐world performance of the <scp>DBLG1</scp> closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany mā Pierre‐Yves Benhamou, Alice Adenis, Hocine Lebbad, Yousra Tourki, Maria‐Belen Heredia, Bernhard Gehr, Sylvia Franc, G. Charpentier

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Implication of the Pro12Ala polymorphism of the PPAR-gamma 2gene in type 2 diabetes and obesity in the French population

    Implication of the Pro12Ala polymorphism of the PPAR-gamma 2gene in type 2 diabetes and obesity in the French population mā Maya Ghoussaini, Stephen Eyre, Stéphane Lobbens, G. Charpentier, Karine Clément, Marie‐Aline Charles, M. Tauber, Jacques Weill, Philippe Froguel

    I whakaputaina 2005
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials mā Bo Åhrén, Stephen L. Atkin, G. Charpentier, Mark Warren, John Wilding, Stephen Birch, Anders G. Holst, Lawrence A. Leiter

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies

    The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies mā Stéphane Cauchi, Kevin T. Nead, Hélène Choquet, Fritz Horber, Natascha Potoczna, Beverley Balkau, Michel Marre, G. Charpentier, Philippe Froguel, David Meyre

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

    Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial mā Andrew Ahmann, Matthew Capehorn, G. Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G. Holst, Miriam Annett, Vanita R. Aroda

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System

    Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System mā Pierre‐Yves Benhamou, Alice Adenis, Yousra Tourki, Sylvie Pou, Stéphanie Madrolle, Sylvia Franc, Dulanjalee Kariyawasam, Jacques Beltrand, David C. Klonoff, G. Charpentier

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Genetic Analysis of <i>ADIPOR1</i> and <i>ADIPOR2</i> Candidate Polymorphisms for Type 2 Diabetes in the Caucasian Population

    Genetic Analysis of <i>ADIPOR1</i> and <i>ADIPOR2</i> Candidate Polymorphisms for Type 2 Diabetes in the Caucasian Population mā Martine Vaxillaire, Aurélie Dechaume, Valérie Vasseur-Delannoy, Saida Lahmidi, Vincent Vatin, Frédéric Leprêtre, Philippe Boutin, Serge Herçberg, G. Charpentier, Christian Dina, Philippe Froguel

    I whakaputaina 2006
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study

    Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study mā Dured Dardari, Sylvia Franc, G. Charpentier, L. Orlando, Elise Bobony, Marie Bouly, I. Xhaard, Zohra Amrous, Khadijatou Ly Sall, B. Detournay, A. Penfornis

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

    Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial mā John Wilding, G. Charpentier, Priscilla Hollander, Guillermo González-Gálvez, Chantal Mathieu, Frank Vercruysse, Keith Usiskin, Ga‐Lai Law, Simon Black, William Canovatchel, Gary Meininger

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Impact of Common Type 2 Diabetes Risk Polymorphisms in the DESIR Prospective Study

    Impact of Common Type 2 Diabetes Risk Polymorphisms in the DESIR Prospective Study mā Martine Vaxillaire, J Veslot, Christian Dina, Christine Proença, Stéphane Cauchi, G. Charpentier, Jean Tichet, Frédéric Fumeron, Michel Marre, David Meyre, Beverley Balkau, Philippe Froguel

    I whakaputaina 2007
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system

    Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system mā Jean‐Pierre Riveline, J. Teynié, S. Belmouaz, Sylvia Franc, Dured Dardari, Marc Bauwens, Valérie Caudwell, Stéphanie Ragot, Frank Bridoux, G. Charpentier, R. Maréchaud, Samy Hadjadj

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Ketosis-Prone Type 2 Diabetes in Patients of Sub-Saharan African Origin

    Ketosis-Prone Type 2 Diabetes in Patients of Sub-Saharan African Origin mā Franck Mauvais‐Jarvis, Eugène Sobngwi, Raphaël Porcher, Jean‐Pierre Riveline, Jean-Philippe Kévorkian, Christian Vaisse, G. Charpentier, Pierre-Jean Guillausseau, Patrick Vexiau, Jean‐François Gautier

    I whakaputaina 2004
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Quality of Care of People With Type 2 Diabetes in Eight European Countries

    Quality of Care of People With Type 2 Diabetes in Eight European Countries mā Margaret Stone, G. Charpentier, Kris Doggen, Oliver Kuß, Ulf Lindblad, Christiane Kellner, John J. Nolan, Agnieszka Pazderska, Guy E.H.M. Rutten, Marina Trento, Kamlesh Khunti

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Insulin Infusion Set Use: European Perspectives and Recommendations

    Insulin Infusion Set Use: European Perspectives and Recommendations mā Dorothee Deiss, Peter Adolfsson, Marije Alkemade-van Zomeren, Geremia B. Bolli, G. Charpentier, Claudio Cobelli, Thomas Danne, A. Girelli, Heiko Mueller, Carol A. Verderese, Éric Renard

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Insulin‐based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the <scp>DIABRASPORT</scp> randomized study

    Insulin‐based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the <scp>DIABRASPORT</scp> randomized study mā Sylvia Franc, A. Daoudi, A. Pochat, M. Petit, Caroline Randazzo, C. Petit, Martine Duclos, A. Penfornis, Eric Pussard, D. Not, Elsa Heyman, François Koukoui, Chantal Simon, G. Charpentier

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients

    The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients mā G. Charpentier, Pierre‐Yves Benhamou, Dured Dardari, Annie Clergeot, Sylvia Franc, P Schaepelynck-Bélicar, Bogdan Catargi, V. Melki, Lucy Chaillous, Anne Farret, Jean‐Luc Bosson, A. Penfornis

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Transcription Factor <i>TCF7L2</i> Genetic Study in the French Population

    Transcription Factor <i>TCF7L2</i> Genetic Study in the French Population mā Stéphane Cauchi, Stephen Eyre, Christian Dina, Hélène Choquet, Chantal Samson, Sophie Gallina, Beverley Balkau, G. Charpentier, François Pattou, Volodymyr Stetsyuk, Raphaël Scharfmann, Bart Staels, Gema Frühbeck, Philippe Froguel

    I whakaputaina 2006
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial

    Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial mā Dulanjalee Kariyawasam, Carole Morin, Kristina Casteels, C. Le Tallec, Annie Sfez, Cécile Godot, Erik Huneker, Nathalie Garrec, Pierre‐Yves Benhamou, Michel Polak, G. Charpentier, Sylvia Franc, Jacques Beltrand

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: